Mondal S, Pramanik S, Khare VR, Fernandez CJ, Pappachan JM. Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives. World J Cardiol 2024; 16(5): 240-259 [PMID: 38817648 DOI: 10.4330/wjc.v16.i5.240]
Corresponding Author of This Article
Joseph M Pappachan, MD, FRCP, Academic Editor, Professor, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. May 26, 2024; 16(5): 240-259 Published online May 26, 2024. doi: 10.4330/wjc.v16.i5.240
Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives
Sunetra Mondal, Subhodip Pramanik, Vibhu Ranjan Khare, Cornelius James Fernandez, Joseph M Pappachan
Sunetra Mondal, Vibhu Ranjan Khare, Department of Endocrinology, NRS Medical College, Kolkata 700020, West Bengal, India
Subhodip Pramanik, Department of Endocrinology, Neotia Getwel Multispecialty Hospitals, Siliguri 734010, West Bengal, India
Cornelius James Fernandez, Department of Endocrinology and Metabolism, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, Boston PE21 9QS, United Kingdom
Joseph M Pappachan, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom
Joseph M Pappachan, Faculty of Science, Manchester Metropolitan University, Manchester M15 6BH, United Kingdom
Joseph M Pappachan, Faculty of Biology, Medicine & Health, The University of Manchester, Manchester M13 9PL, United Kingdom
Author contributions: Mondal S contributed to the initial drafting of the work by performing the literature search and interpretation of relevant literature with help from Pramanik S and Khare VR; Fernandez CJ prepared the figures for the manuscript and contributed additionally to the drafting process; Pappachan JM conceptualized the idea and provided overall supervision to the drafting process; and all authors contributed to the revision of the article for important intellectual content; All authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Joseph M Pappachan, MD, FRCP, Academic Editor, Professor, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in
Received: December 25, 2023 Revised: April 8, 2024 Accepted: April 28, 2024 Published online: May 26, 2024 Processing time: 149 Days and 20.9 Hours
Core Tip
Core Tip: The new antidiabetic medication class sodium glucose cotransporter-2 inhibitors (SGLT-2i) are found to have remarkable cardiovascular (CV) benefits proven by multiple randomised controlled trials and real-world observational studies. They are also useful in prevention of CV disease (CVD) in patients with diabetes mellitus. The CV benefits of SGLT-2i are not just because of antidiabetic effects. The preventive and management effects of SGLT2i molecules in diabetic and nondiabetic renal disease also translate into CV benefits. This clinical update review compiles the up-to-date evidence on the molecular mechanisms of SGLT-2i in prevention and management of CVD for empowering clinicians to rationalise the use of these molecules in day-to-day medical practice.
